Familial transthyretin (TTR) amyloidosis (FTA) is a serious autosomal dominant neuropathy caused by TTR germline mutations that lead to death on average 10 years from symptom onset. The mutant tetramer protein is produced predominantly in the liver, and liver transplantation is commonly performed to reduce the production of the mutant protein.
He was referred 2 years from neuropathy onset unsafe to walk, having proximal and distal extremity weakness (Medical Research Council strength: 1/5 bilaterally below knees and elbows; 2/5 bilaterally at the thighs and shoulders). He was hyporeflexic and had dense sensory loss for heat pain and proprioception extending to the shins. Nerve conductions were abnormal, compound muscle action potential (peroneal 0.2, normal > 2.0 mV; tibial 0.3, normal > 4.0 mV; ulnar 3.2 mV, normal > 6.0 mV) and sensory nerve action potential (sural 0.0, normal > 0.0 uV; median 0.0, normal > 15 uV; ulnar 2.0, normal uV > 10.0 uv) without demyelination. Needle EMG showed neurogenic potentials with fibrillations extending to the arms and thighs, all consistent with a severe axonal sensorimotor polyneuropathy. Autonomic testing showed patchy postganglionic sudomotor abnormality by quantitative sudomotor autonomic reflex testing and moderate adrenergic and severe cardiovagal impairment by tilt table evaluation with Valsalva maneuver. Echocardiogram was normal 13 months before death, but 99m Tc-hydroxyethylene diphosphonate single-photon emission computed tomography and needle EMG or nerve conductions of the diaphragm were not performed. Urine analysis revealed proteinuria 454 mg (normal <167 mg/24 hours), with creatinine clearance 68 mL/min (normal 77-130 mL/min/body surface area). Multiple tests were unremarkable: serum immunofixation, CSF PCR (cytomegalovirus, Epstein-Barr virus, and burgdorferi), serum thryoid stimulating hormone, B12, folate, copper, C-reactive protein, MRI of the spine, CT of the chest-abdomenpelvis, and bone marrow flow cytometry for lymphoma.
Sural nerve and bone marrow biopsies showed infiltration by amyloid with occasional inflammatory cells seen in the nerve (figure). TTR DNA sequencing from his blood was negative for mutation. Liquid chromatography-tandem mass spectrometry (LC-MS/MS) performed on the amyloid infiltration from the bone marrow and nerve specimens confirmed TTR p.Val71Ala amyloidosis in both specimens (figure). Repeat liver transplant was considered, but he was not a candidate based on the severity of neuropathy and his age. He was unable to tolerate diflunisal due to gastrointestinal upset. He died 5 years and 1 month from the time of transplantation with respiratory failure.
Discussion
Amyloid transthyretin p.Val71Ala amyloidosis has been associated with young onset of disease (in the 30s and 40s), as occurred in the living donor of our patient. 3 Recent 20-year review of the familial amyloid polyneuropathy World Transplant Registry identifies 11 TTR p.Val71Ala persons having undergone liver transplant. 1 One p.Val71Ala DLTX recipient aged 59 years developed neuropathy and cardiomyopathy 5 years after transplant but was still alive 9 years later. 4 Our patient was considerably older (70 years) at the time of transplant, and older age has been identified as an important accelerator of domino recipient amyloid neuropathy. 5 The limited inflammation in our case seems coincidental occurring in up to one-third or amyloid sural nerve biopsies. 6 The problems experienced by domino recipients related to mutant TTR are increasingly recognized. Prospective investigations of neuropathy within domino recipients have identified common (one-fourth affected) pathologic nerve amyloid infiltration with symptomatic neuropathy. 7 Although patients were reported to have symptoms mimic FTA, our patient seems to have worse severity.
Neurologic improvements in FTA can occur not only in those receiving early-onset liver transplantation 1 but also those treated early with the new FDA-approved drugs.
2 A theoretical advantage of the new oligonucleotide therapies is that they reduce both wild-type and mutant TTR, both linked to disease progression. However, before consideration of these drugs in DLTX-affected patients, mutant TTR will likely need to be confirmed by LC MS/MS, as diagnosis of mutant TTR by blood DNA will not be possible. 
